Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing […]

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring […]

May 27, 2021 – Taiho Pharmaceutical Co., Ltd.  and Helsinn Healthcare SA, which is headquartered in Lugano, Switzerland , announced today that Taiho has acquired […]

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce […]

Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first […]

Lugano, Switzerland, April 13, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce […]

BridgeBio, through its Affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. […]

Lugano, Switzerland, March 23, 2021 – Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) is pleased to announce that its Japanese partner Taiho Pharmaceutical Co., […]

Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note […]

Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note […]